Tixagevimab/cilgavimab pre‐exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

(2022) Heba N. Altarawneh et al.   NEW ENGLAND JOURNAL OF MEDICINE

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

(2022) Yueh-Ming Loo et al.   Science Translational Medicine

Efficacy of anti–SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients

(2022) Dominique Bertrand et al.   KIDNEY INTERNATIONAL

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2

(2022) Yair Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

(2022) Myron J. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

(2022) Ori Magen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination

(2022) Ayman Al Jurdi et al.   Frontiers in Immunology

Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study

(2021) Megan M Sheehan et al.   CLINICAL INFECTIOUS DISEASES

Is Covid‐19 infection more severe in kidney transplant recipients?

(2020) Sophie Caillard et al.   AMERICAN JOURNAL OF TRANSPLANTATION